Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti–PD-1 efficacy in colorectal cancer
Year: 2026
Type: article
Source: Science Translational Medicine
Institutions: Sun Yat-sen University, Westlake University, Sixth Affiliated Hospital of Sun Yat-sen University, Shenzhen Bay Laboratory, Shenzhen Medical Academy of Research and Translation, Nanchang University, First Affiliated Hospital of Jiangxi Medical College, First Affiliated Hospital of Nanchang University, Chinese Academy of Sciences, Shenzhen Institutes of Advanced Technology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Jinan University, University of Hong Kong, Sun Yat-sen Memorial Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: colorectal cancer, tumor immune evasion, folate receptor alpha, antibody-drug conjugates, mirvetuximab soravtansine, anti-PD-1 therapy, immune checkpoint inhibitor resistance, MHC class I loss, AARS1, TCPTP, c-Myc, cancer stemness, tumor microenvironment, CD8+ T cell infiltration, CRISPR activation screen, combination immunotherapy
Open Access status: closed
OpenAlex ID: W7236404203
